J. Shi

Complementing Tissue Testing with Plasma mutation Profiling Improves Therapeutic Decision Making for Lung Cancer Patients

A. Tee, J. Poh, K. Ngeow, 2021, medRxiv.

OA01.08 A Phase I Study to Evaluate Safety and Antitumor Activity of BPI-7711 in EGFRM+/T790M+ Advanced or Recurrent NSCLC Patients

J. Fang, X. Li, Y. Shu, 2019, Journal of Thoracic Oncology.

Chinese Herbal Medicine (Yiqi-Yangyin-Jiedu Decoction) Combined With Osimertinib As First-Line Treatment For Advanced Non-Small-Cell Lung Cancer With EGFR Sensitizing Mutation (CATLA-2): A Study Protocol For A Double-Blind Randomized Controlled Trial

Y. Lu, L. Xu, L. Jiao, 2021 .

1338PEGFR mutation detection in plasma cell-free DNA correlates with clinical outcomes in non-small cell lung cancer

T. Chin, D. Chan, C. Toh, 2017 .

Whole brain radiation therapy followed by intensity-modulated boosting treatment combined with concomitant temozolomide for brain metastases from non-small-cell lung cancer

C. Leng, S. Lu, Shiyong Lu, 2014, Clinical and Translational Oncology.

The value of eosinophil VCS parameters in predicting hepatotoxicity of antituberculosis drugs

J. Shi, D. Gu, D. Xu, 2016, International journal of laboratory hematology.

Distinct molecular phenotype and the potential prognostic value of immune prognostic index and tumor infiltrating lymphocytes in hepatoid adenocarcinoma of stomach

Xiaojing Ma, Pintong Huang, Jinghong Xu, 2022, Translational oncology.